P

Inventor

HUANG RICHARD Y

US20 patents
⚠️ This page may combine multiple inventors who share the name “HUANG RICHARD Y”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

BRISTOL MYERS SQUIBB CO

16 patents
US10100129B2Oct 16, 2018

Antibodies against CD73 and uses thereof

BRISTOL MYERS SQUIBB CO24 citations93
US11213586B2Jan 4, 2022

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

BRISTOL MYERS SQUIBB CO5 citations72
US10690674B2Jun 23, 2020

Anti-GITR antibodies for cancer diagnostics

BRISTOL MYERS SQUIBB CO5 citations71
US10167343B2Jan 1, 2019

Antibodies against CD73

BRISTOL MYERS SQUIBB CO3 citations71
US11524992B2Dec 13, 2022

Glypican-3-binding fibronectin based scaffold molecules

BRISTOL MYERS SQUIBB CO2 citations70
US10584160B2Mar 10, 2020

Glypican-3-binding fibronectin based scaffold molecules

BRISTOL MYERS SQUIBB CO3 citations70
US12077584B2Sep 3, 2024

Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)

BRISTOL MYERS SQUIBB CO1 citations69
US11274150B2Mar 15, 2022

Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies

BRISTOL MYERS SQUIBB CO2 citations69
US10556948B2Feb 11, 2020

IP-10 antibodies and their uses

BRISTOL MYERS SQUIBB CO2 citations69
US11242393B2Feb 8, 2022

Antibodies against MICA and/or MICB and uses thereof

BRISTOL MYERS SQUIBB CO3 citations67
US12110337B2Oct 8, 2024

Anti-CD27 antibodies and uses thereof

BRISTOL MYERS SQUIBB CO0 citations62
US11408889B2Aug 9, 2022

Anti-GITR antibodies for cancer diagnostics

BRISTOL MYERS SQUIBB CO1 citations61
US11352440B2Jun 7, 2022

Antibodies against CD73 and uses thereof

BRISTOL MYERS SQUIBB CO0 citations61
US12492238B2Dec 9, 2025

Glypican-3-binding fibronectin based scaffold molecules

BRISTOL MYERS SQUIBB CO0 citations59
US11981734B2May 14, 2024

Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)

BRISTOL MYERS SQUIBB CO0 citations59
US11708405B2Jul 25, 2023

IP-10 antibodies and their uses

BRISTOL MYERS SQUIBB CO1 citations58

FIVE PRIME THERAPEUTICS INC

4 patents